Stable castration level of testosterone in androgendeprivation therapy for clear cell renal cell carcinoma
https://doi.org/10.18027/2224-5057-2015-1-42-48
Abstract
One of the most important strategies for treating prostate cancer is to achieve and maintain effective suppression of testosterone levels in men receiving androgen deprivation. Historically, testosterone levels below 50 ng/dl was regarded as castration level. Current data indicate that in an attempt to maximize the therapeutic result of a new target for any surgical or chemical castration is a testosterone level below 20 ng/dl. The phenomenon of flash testosterone and exacerbation of chronic conditions by introducing an analog of luteinizing hormone releasing hormone can cause testosterone levels to rise periodically, sometimes up to a non-castration levels. The study of androgen ablation is to identify those agents with which achieved and maintained lowest levels of testosterone.
About the Authors
A. A. Gritskevich
Institute of Surgery A.V. Vishnevsky
Russian Federation
Moscow
Russian Federation
Moscow
S. V. Mishugin
Moscow City Clinical Hospital № 57
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Teplov
Institute of Surgery A.V. Vishnevsky
Russian Federation
Moscow
Russian Federation
Moscow
I. G. Rusakov
Moscow City Clinical Hospital № 57
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Kaprin A.D., Starinskyj V.V., Petrova G.V. Malignant tumors in Russia in 2012. Moscow.2014.
2. Pagliarulo, V. Contemporary role of androgen deprivation therapy for prostate cancer/Pagliarulo, V. [et al.] // Eur.Urol.— 2012.— Vol.61.— Р. 11–25.
3. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010; 363: 1822–1832.
4. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schr der FH. Contemporary role of androgen deprivation therapy for prostate cancer. EurUrol 2012; 61: 11–25.
5. Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2013 Oct 8. pii: S0959–8049 (13) 00842.
6. De Angelis R, Sant M, Coleman MP, et al; EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. LancetOncol 2014 Jan;15 (1):23–34.)
7. Cancer incidence in Sweden 2004. The National Board of Health and Welfare: Stockholm.
8. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU Guidelines on prostate cancer. Part I: screening, diagnosis and treatment of clinically localized disease. EurUrol 59:61–71.
9. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. EurUrol 59:572–583.
10. Studer UE, Whelan P, Albrecht W et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: europeanOrganisation for Research and Treatment of Cancer (EORTC) Tria 30891. J ClinOncol 24 (12):1868–1876.
11. Small EJ, Ryan CJ (2006) The case for secondary hormonal therapies in the chemotherapy age. J Urol 176 (6 Pt 2):66–7.
12. Koutsilieris M, Dimopoulos T, Milathianakis C et al (2007) Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU Int 100 (Suppl 2):60–62.
13. Serrate C, Loriot Y, De La Motte Rouge T et al (2009) Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 20 (5):965.
14. Tunn UW (2011) A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1,273 patients. BMC Urol 11:15.
15. Rosette J de la, Davis R 3rd, Frankel D, KoldOlesen T (2011) Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J ClinPract 65 (5):559–566.
16. Crawford ED, Tombal B, Miller K et al (2011) A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. JUrol 186 (3):889–897.
17. Raddin RS, Walko CM, Whang YE (2011) Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. Anticancer Drugs 22 (3):299–302.
18. Sarosdy MF, Schellhammer PF, Soloway MS et al (1999) Endocrine effects, efficacy and tolerability of a 10.8- mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 83 (7):801–806.
19. Oefelein MG, Cornum R (2000) Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (3 Pt 1):726–729.
20. McLeod D, Zinner N, Tomera K et al (2001) Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58 (5):756–761.
21. Morote J, Orsola A, Planas J et al (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178 (4 Pt 1):1290–1295.
22. Schulman CC, Irani J, Morote J et al (2010) Testosterone measurement in patients with prostate cancer. EurUrol 58 (1):65–74.
23. Heyns CF, Simonin MP, Grosgurin P et al (2003) Comparative efficacy of triptorelinpamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 92 (3):226–231.
24. Radu A, Pichon C, Camparo P et al (2010) Expression of follicle stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621–1630.
25. Porcara AB, Migliorini F, Petrozziello A et al (2011) Investigative clinical study on prostate cancer part IV: follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. UrolInt (Epub ahead of print).
26. Tombal B, Berges R (2008) Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. EurUrol (Suppl 7):15–28.
27. Gomella LG (2009) Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol 11:52–60.
28. Pickles T, Tyldesly S (2011) Testosterone breakthrough during LHRH agonist androgen deprivation with curative radiation: impact on PSA kinetics and subsequent biochemical outcomes. 26th Annual Congress of the European Association of Urology, Vienna, Austria.
29. Perachino M, Cavalli V, Bravi F (2010) Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105:648–65.
30. Taplin ME, Regan MM, Ko YJ et al (2009) Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 15 (22):7099–7105.
31. Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men castrate nonmetastatic prostate cancer. J ClinOncol 23:2918–2925.
Review
For citations:
Gritskevich A.A., Mishugin S.V., Teplov A.A., Rusakov I.G. Stable castration level of testosterone in androgendeprivation therapy for clear cell renal cell carcinoma. Malignant tumours. 2015;(1):46-53. (In Russ.) https://doi.org/10.18027/2224-5057-2015-1-42-48
Views:
4182
Email this article 